Chronic Intestinal Pseudo-Obstruction Clinical Trial
— POMOfficial title:
A Case-control Study of the Gastrointestinal Response to a Liquid Test Meal in Chronic Intestinal Pseudo-obstruction, Using Magnetic Resonance Imaging
NCT number | NCT04193735 |
Other study ID # | 19069 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | January 17, 2020 |
Est. completion date | December 30, 2024 |
This study will explore the potential for a standardized MRI scan after a liquid meal to be used in diagnosis of the rare but debilitating chronic intestinal pseudo-obstruction (CIPO).
Status | Recruiting |
Enrollment | 16 |
Est. completion date | December 30, 2024 |
Est. primary completion date | December 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years and older |
Eligibility | Inclusion Criteria: - Ability to give informed consent - Sufficient level of English language to understand study information and respond to symptom questionnaires - CASES: a clinical diagnosis of primary or secondary Chronic Intestinal Pseudo-Obstruction, excluding adhesional obstruction. PICs will be asked to send clinical documentation that the diagnosis has been confirmed on crosssectional imaging. - CONTROLS: a Chronic constipation disorder diagnosed according to Rome IV criteria for functional constipation, constipation-predominant irritable bowel syndrome or opioid-induced constipation (diagnostic criteria as listed in Lacy et al 2016) Exclusion Criteria: - Inability to tolerate 400 ml liquid challenge meal (oral or through established gastrostomy; according to self-assessment) - Contra-indication to MRI scanning, such as metal implants, pacemaker etc - Pregnancy declared by candidate (no formal testing) - Inability to stop short-acting medications likely to alter small bowel motility, such as antiemetics, fast release opioids, laxatives, and anti-diarrhoeals, on the day before the study (24h before baseline scan; i.e. a total of circa 30h) as well as antibiotics for three days before the study. This only applies to long-term antibiotics commonly given for dysbiosis (small intestinal bacterial overgrowth). A short course of antibiotics given for acute infections will not be interrupted but the study day will be delayed until the course is finished. Patches, long acting formulations such as slow release medication or depot injection medication will be allowed to continue - Inability to omit parenteral nutrition for 12 hours before the fasting MRI scan (~16h total) - Medical comorbidity that means subject will not be able to undergo multiple scans e.g. severe respiratory disorder limiting time lying flat; severe musculoskeletal disorder limiting mobility - Previous small bowel resection (excluding ileostomy, insertion of venting tube or percutaneous endoscopic gastrostomy, appendectomy or cholecystectomy). Patients who have had a colectomy for their CIPO will be eligible. - Other gastrointestinal disorder likely to alter small bowel function e.g. uncontrolled coeliac disease, Crohn's disease. A diagnosis of small intestinal bacterial overgrowth will not be a reason for exclusion. PICs will be asked to supply information on resections and comorbidities for CIPO participants. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | University of Nottingham | Nottingham | Nottinghamshire |
Lead Sponsor | Collaborator |
---|---|
University of Nottingham | Barts & The London NHS Trust, Cambridge University Hospitals NHS Foundation Trust, London North West Healthcare NHS Trust, Manchester University NHS Foundation Trust, Northern Care Alliance NHS Foundation Trust, Oxford University Hospitals NHS Trust, Pseudo-Obstruction Research Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Peak small gut motility after a test liquid meal | Investigating whether people with CIPO have a lower peak small gut motility after a test drink than people who do not have CIPO. Small gut motility will be assessed with a standardised method on CineMRI, based on power spectrum analysis of voxel-signal changes with time (the outcome will be reported in arbitrary units). The primary outcome is peak small gut motility since a delay in motility (linked to one specific time point) would not be sufficient to explain the difference between CIPO and controls. | up to 3.5 hours after meal, measured every half hour | |
Secondary | Gastric emptying rate (ml/min) after a test liquid meal | Investigating whether people with CIPO have slower gastric emptying after a test drink than people who do not have CIPO. The gastric emptying rate is determined by measuring the gastric volume every half hour after the standardised meal. | up to 3.5 hours after meal, measured every half hour | |
Secondary | Small bowel water volume (ml) after a test liquid meal | Investigating whether people with CIPO have a greater volume of small bowel water after a test drink than people who do not have CIPO. Small bowel water content is determined from a heavily T2-weighted scan. The intensity threshold for free water will be set using each participant's spinal fluid, and only small bowel contents having an intensity equal to or greater than this value will be measured as small bowel free water volume. | up to 3.5 hours after meal, measured every half hour | |
Secondary | Gastric motility after a test liquid meal | Investigating whether people with CIPO have a reduced gastric motility after a test drink than people who do not have CIPO. Gastric motility will be assessed with a standardised method on CineMRI, based on power spectrum analysis of voxel-signal changes with time (the outcome will be reported in arbitrary units). | up to 3.5 hours after meal, measured every half hour |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04506593 -
Indiana University Gastrointestinal Motility Diagnosis Registry
|
||
Active, not recruiting |
NCT04118699 -
Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial
|
Phase 2 | |
Active, not recruiting |
NCT05724069 -
Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).
|
Phase 2 | |
Completed |
NCT00793247 -
Efficacy Study of Prucalopride to Treat Chronic Intestinal Pseudo-Obstruction (CIP)
|
Phase 2 |